ライフサイエンスコーパス: rt-PA

1 re: 1) Ep (n = 6); 2) Ep + rt-PA (n = 6); 3) rt-PA (n = 6); and 4) placebo (n = 4).

2 The recombinant tissue plasminogen activator rt-PA has been shown to significantly increase the numbe

3 combinant tissue-type plasminogen activator (rt-PA) (alpha half-life 4.5 min) or to placebo followed

4 us recombinant tissue plasminogen activator (rt-PA) after ischaemic stroke improves outcome.

5 us recombinant tissue plasminogen activator (rt-PA) are discussed.

6 ed recombinant tissue plasminogen activator (rt-PA) directly before reperfusion, and assessed neurolo

7 ombinant human tissue plasminogen activator (rt-PA) glycoprotein.

8 V) recombinant tissue plasminogen activator (rt-PA) has been demonstrated, endovascular therapy is an

9 combinant tissue-type plasminogen activator (rt-PA) improves outcomes for patients with acute ischemi

10 ombined with low-dose plasminogen activator (rt-PA) inhibits platelet recruitment at sites of endothe

11 Recombinant tissue plasminogen activator (rt-PA) is a well-characterized glycoprotein with a great

12 ly recombinant tissue plasminogen activator (rt-PA), 1 mg per lumen, once per week, and twice-weekly

13 ng recombinant tissue plasminogen activator (rt-PA), 3) cannulating the retinal vein transvitreally,

14 e thrombolytic tissue plasminogen activator (rt-PA), is approved by the FDA for use in patients with

15 combinant tissue-type plasminogen activator (rt-PA, Activase) to methionine oxidation when treated wi

16 Recombinant tissue plasminogen activator (rt-PA, alteplase) improved functional outcome in patient

17 combinant tissue-type plasminogen activator [rt-PA]).

18 different between the two groups (6.2% after rt-PA and 5.6% after PTCA).

19 c-eligible patients not in shock: 5.4% after rt-PA and 5.2% after PTCA.

20 ence in the rate of reinfarction (2.9% after rt-PA and 2.5% after PTCA).

21 with increased risk of adverse outcome after rt-PA treatment.

22 tality was higher in patients in shock after rt-PA than after PTCA (52% vs. 32%, p < 0.0001).

23 nt difference in the mean overall cost of an rt-PA/heparin strategy as a locking solution for cathete

24 tic-eligible patients not in shock, PTCA and rt-PA are comparable alternative methods of reperfusion

25 threatening/serious systemic hemorrhage, any rt-PA complication, in-hospital mortality, and modified

26 aracterization of familiar proteins, such as rt-PA, using the new capabilities of modern analytical t

27 alence of EIC on baseline CT in the combined rt-PA and placebo groups was 31% (n = 194).

28 Short-term infusion Ep plus low-dose rt-PA acutely neutralizes the ability of damaged endothe

29 Ep plus reduced-dose rt-PA has not previously been shown to render a recanali

30 reatment groups were: 1) Ep (n = 6); 2) Ep + rt-PA (n = 6); 3) rt-PA (n = 6); and 4) placebo (n = 4).

31 hrombus and platelet aggregates only in Ep + rt-PA treated arteries.

32 re randomized to Ep alone (n = 5) or to Ep + rt-PA (n = 5).

33 telet aggregates with Ep alone and with Ep + rt-PA, but not with rt-PA alone.

34 ischaemic stroke patients meet criteria for rt-PA; therefore, alternative acute treatment strategies

35 all the evidence from randomised trials for rt-PA in acute ischaemic stroke in an updated systematic

36 TBHP, while three of the five methionines in rt-PA were found to be oxidizable.

37 tetrasaccharides, not previously observed in rt-PA.

38 we identified two novel glycan structures in rt-PA.

39 of the peptides and glycopeptide variants in rt-PA.

40 Intravenous rt-PA (recombinant tissue-type plasminogen activator) is

41 esults do not support the use of intravenous rt-PA for stroke treatment beyond 3 hours.

42 luate the safety and efficacy of intravenous rt-PA in patients with ischemic stroke who are taking NO

43 earched for randomised trials of intravenous rt-PA versus control given within 6 h of onset of acute

44 ION: The evidence indicates that intravenous rt-PA increased the proportion of patients who were aliv

45 effect of time to treatment with intravenous rt-PA (alteplase) on therapeutic benefit and clinical ri

46 ith ischemic stroke treated with intravenous rt-PA within 4.5 hours, 251 were taking NOACs (dabigatra

47 et population, 32% of the placebo and 34% of rt-PA patients had an excellent recovery at 90 days (P =

48 teine) could shed light on the activation of rt-PA, upon stimulation by either oxidative or ischemic

49 0001) but were normalized by the addition of rt-PA.

50 lated bacteremia, and whether the benefit of rt-PA on catheter-related bacteremia was maintained in t

51 The benefit of rt-PA was greatest in patients treated within 3 h (mRS 0

52 Complications of rt-PA therapy, such as haemorrhagic transformation and a

53 remia partially offset the increased cost of rt-PA.

54 ion to the characterization of glycoforms of rt-PA.

55 dian time from presentation to initiation of rt-PA in the thrombolytic group was 42 min; the median t

56 symptom onset and prior to the initiation of rt-PA or placebo.

57 Administration of 0.9 mg/kg of rt-PA (n = 272) or placebo (n = 275) intravenously over

58 an structures based on existing knowledge of rt-PA glycans.

59 An approach to management of rt-PA complications is outlined.

60 e; however, there are few data on the use of rt-PA in patients who are receiving a non-vitamin K anta

61 on using decision analysis, assuming ongoing rt-PA effectiveness, the overall costs of the strategies

62 Recombinant t-PA (rt-PA) induced exocytotic and carrier-mediated NE releas

63 INDINGS: In up to 12 trials (7012 patients), rt-PA given within 6 h of stroke significantly increased

64 Recombinant tissue plasminogen (rt-PA) with 35 cysteine residues has been completely ass

65 ng solution was higher in patients receiving rt-PA/heparin, but this was partially offset by lower co

66 This study found no significant rt-PA benefit on the 90-day efficacy end points in patie

67 twice-weekly heparin as a locking solution (rt-PA/heparin) resulted in lower risks of hemodialysis c

68 these preliminary observations suggest that rt-PA appears to be reasonably well tolerated without pr

69 g that EIC is unlikely to affect response to rt-PA treatment.

70 in anticoagulation increased HT secondary to rt-PA treatment as compared to nonanticoagulated control

71 Although experience of using rt-PA in patients with ischemic stroke on a NOAC is limi

72 90 days was 6.9% with placebo and 11.0% with rt-PA (P = .09).

73 Patency on cath lab arrival was 61% with rt-PA (28% Thrombolysis in Myocardial Infarction trial [

74 The risk of symptomatic ICH increased with rt-PA treatment.

75 h Ep alone and with Ep + rt-PA, but not with rt-PA alone.

76 on to treat otherwise eligible patients with rt-PA within 3 hours of stroke onset.

77 djusted mean cost for managing patients with rt-PA/heparin versus heparin alone was Can$323 (95% CI,

78 hours was detected in the group treated with rt-PA (P>/=.22).

79 Patients treated with rt-PA did better whether or not they had EICs, suggestin

80 In the first 10 days treatment with rt-PA significantly increased the rate of symptomatic in